| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H29FN4O4 |
| Molecular Weight | 468.5206 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=C(NC2=C1C(=O)N(C[C@H](O)CN3CCOCC3)CCC2)\C=C4/C(=O)NC5=C4C=C(F)C=C5
InChI
InChIKey=MCTXSDCWFQAGFS-UEXNTNOUSA-N
InChI=1S/C25H29FN4O4/c1-15-22(12-19-18-11-16(26)4-5-20(18)28-24(19)32)27-21-3-2-6-30(25(33)23(15)21)14-17(31)13-29-7-9-34-10-8-29/h4-5,11-12,17,27,31H,2-3,6-10,13-14H2,1H3,(H,28,32)/b19-12-/t17-/m1/s1
| Molecular Formula | C25H29FN4O4 |
| Molecular Weight | 468.5206 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Henatinib was developed as a multitargeted tyrosine kinase inhibitor with antitumor activities. Henatinib is an endothelial growth factor receptor type 2 (VEGFR2) antagonist. The drug participated in phase I clinical trial to evaluate the safety and tolerability in patients with advanced solid malignancies, however, the study was terminated. The current development status is unknown.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
